Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTX-102 in pediatric Angelman Syndrome
NCT04259281Phase 2Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Feb 2020
- Primary completion
- Jan 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 8
01
Overview
A Phase 2 trial of apazunersen in Angelman syndrome (AS), sponsored by Ultragenyx Pharmaceutical Inc.. Started Feb 2020; status: completed.
02
Drugs
apazunersen
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT04259281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04259281.